Clinical Trials in Hechi, Guangxi
2 recruiting
Showing 1–2 of 2 trials
Recruiting
Phase 2
Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
MSI-H/dMMR Solid Tumors
BeiGene200 enrolled29 locationsNCT03736889
Recruiting
Phase 3
A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years
HPV-Related CarcinomaHPV Infection
National Vaccine and Serum Institute, China13,500 enrolled8 locationsNCT05262010